Surrozen Publishes Study in 'eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches Surrozen's current SWEETS bispecific antibodies are unique TPD technologies Results

GlobeNewswireJun 12 08:30 ET

Express News | Surrozen Inc: Phase 1a Trial of Szn-043 Demonstrated Evidence of Target Engagement and Wnt-Pathway Mediated Pharmacodynamic Effects in Liver

ReutersJun 10 08:30 ET

Express News | Surrozen Inc: Treatment With Szn-043 in Phase 1a Trial Was Safe & Well Tolerated in Healthy Volunteers and Patients With a History of Liver Cirrhosis

ReutersJun 10 08:30 ET

Express News | Surrozen Presents Preliminary Results From Phase 1a Study of Szn-043 in Healthy Volunteers and Patients With a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (Easl) in Milan

ReutersJun 10 08:30 ET

Express News | Surrozen Announces First Patient Dosed In Phase 1b Trial Of SZN-043 For Severe Alcohol-Associated Hepatitis

BenzingaJun 4 08:31 ET

Express News | Surrozen : Szn-043 Clinical Trial Program in Severe Alcohol-Associated Hepatitis & Anticipate That Proof-of-Concept Data May Be Available in H1 2025

ReutersJun 4 08:31 ET